Atara Biotherapeutics Announces Completion Of The ATA188 Phase 2 EMBOLD Study Interim Analysis In Patients With Progressive MS

 Independent Data and Safety Monitoring Committee Recommends Continuing Study Without Sample Size Adjustment  

IDSMC Did Not Identify Any Safety Concerns

Phase 2 Study Target Enrollment Achieved; Final Data and Communication Expected in October 2023

Conference Call and Webcast Today at 2:00 p.m. PDT/5:00 p.m. EDT